Last updated on June 2019

Exploratory Study to Investigate the Bioactivity Ocular and Systemic Safety Tolerability and Pharmacokinetics Following Single and Multiple Intravitreal Administrations of KSI-301 in Subjects With wAMD DME and RVO


Brief description of study

This is a Phase 1b open-label study to assess the bioactivity, ocular and systemic safety, tolerability, and pharmacokinetics of repeated injections of KSI-301 at two dose levels: 2.5 mg and 5 mg

Clinical Study Identifier: NCT03790852

Find a site near you

Start Over